Xueqi Chen

Peking University

Papers

1

Total Citations

15

H-Index

1

About

Dr. Xueqi Chen is a pioneering figure in molecular imaging and precision oncology, whose work centers on developing targeted probes for cancer diagnosis and therapy. Her most notable contribution is the first-in-human study of a dual-modality prostate-specific membrane antigen (PSMA)–targeted probe, which integrates preoperative positron emission tomography/computed tomography (PET/CT) imaging with intraoperative fluorescence imaging for prostate cancer. This groundbreaking research, published in 2025 and already garnering 15 citations, demonstrates her ability to bridge diagnostic imaging and surgical guidance, offering a transformative approach to tumor localization and resection. Dr. Chen’s work addresses a critical need in urologic oncology, where precise detection and removal of cancerous tissue can significantly improve patient outcomes. By validating this multimodal probe in a clinical setting, she has laid the foundation for more accurate, real-time surgical interventions. Her achievements highlight her expertise in radiochemistry, molecular imaging, and translational medicine, positioning her as a leader in the development of theranostic agents. Dr. Chen’s research continues to inspire advances in personalized cancer care, making her a key voice in the future of image-guided surgery.

Research Focus

Key Achievements

1
H-Index
1
Papers
15
Total Citations
15
Avg Citations/Paper
🏆 Most Cited Paper
First-in-human Study of a Dual-modality Prostate-specific Membrane Antigen–targeted Probe for Preoperative Positron Emission Tomography/Computed Tomography Imaging and Intraoperative Fluorescence Imaging in Prostate Cancer
15 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: Peking University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago